​​​​​​​PsA Treatment Options Expand

• by Kathryn Wighton

• March 9, 2026

Psoriasis Biologics Face Off in Drug Survival Study 

Danish registry data reveal differences in treatment persistence

• by Julie Greenbaum

• January 14, 2026

• 2 min

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

• by Kathryn Wighton

• March 18, 2026

• 2 min

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

• by Kathryn Wighton

• June 29, 2026

• 3 min